Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report published on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of NASDAQ:CHEK opened at $2.30 on Tuesday. The firm’s 50 day simple moving average is $2.25 and its 200-day simple moving average is $2.56. Check-Cap has a one year low of $1.27 and a one year high of $4.63. The firm has a market cap of $13.46 million, a PE ratio of -0.76 and a beta of 0.28.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.